849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Breast Cancer	M.D. Anderson Cancer Center	P3	B (57)
Copanlisib Breast Cancer	National Cancer Institute (NCI)	P2	B (57)
Edotreotide Breast Cancer	University Hospital, Grenoble	P3	B (57)
eg1206a Breast Cancer	EirGenix, Inc.	P3	B (57)
GB491 Breast Cancer	Genor Biopharma Co., Ltd.	P3	B (57)
Ibuprofen Breast Cancer	Aga Khan University	P4	B (57)
Lansoprazole Breast Cancer	The Christie NHS Foundation Trust	P3	B (57)
Niraparib Breast Cancer	Canadian Cancer Trials Group	P3	B (57)
Odetiglucan Breast Cancer	HiberCell, Inc.	P2	B (57)
Simvastatin Breast Cancer	Emory University	P3	B (57)
sph4336 Breast Cancer	Shanghai Pharmaceuticals Holding Co., Ltd	P2/3	B (57)
Tenalisib Breast Cancer	Rhizen Pharmaceuticals SA	P2	B (57)
Vorinostat Breast Cancer	University of California, San Francisco	P2	B (57)
16.ALPHA.-FLUOROESTRADIOL Breast Cancer	Abramson Cancer Center at Penn Medicine	P4	B (56)
Anti-Her2 Antibody-Drug Conjugate A166 Breast Cancer	Fudan University	P2	B (56)
Apsolol Breast Cancer	Chang-Ik Yoon	P4	B (56)
Azacitidine Breast Cancer	National University Hospital, Singapore	P2	B (56)
Bazedoxifene Breast Cancer	University of Kansas Medical Center	P2	B (56)
Bicalutamide Breast Cancer	Icahn School of Medicine at Mount Sinai	P2	B (56)
Cabozantinib Breast Cancer	M.D. Anderson Cancer Center	P2	B (56)
Diclofenac Breast Cancer	The Second Affiliated Hospital of Hainan Medical University	P4	B (56)
Enobosarm Breast Cancer	Veru Inc.	P3	B (56)
Entinostat Breast Cancer	Tianjin Medical University Cancer Institute and Hospital	P3	B (56)
Gentamicin Breast Cancer	Memorial Sloan Kettering Cancer Center	P4	B (56)
Jnj-54135419 Breast Cancer	Chinese PLA General Hospital	P4	B (56)
Patritumab Deruxtecan Breast Cancer	Merck Sharp & Dohme LLC	P2	B (56)
Vancomycin Breast Cancer	Jewish General Hospital	P4	B (56)
Vistusertib Breast Cancer	AstraZeneca	P2	B (56)
Zanidatamab Breast Cancer	MedSIR	P2	B (56)
azd8931 Breast Cancer	UNICANCER	P2	CCC (55)
Citalopram Breast Cancer	Hospital Universitari de Bellvitge	P3	CCC (55)
Cobimetinib Breast Cancer	OHSU Knight Cancer Institute	P2	CCC (55)
ds-8201a Breast Cancer	MedSIR	P2	CCC (55)
Famotidine Breast Cancer	Noha Mansour	P2/3	CCC (55)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Breast Cancer	City of Hope Medical Center	P2	CCC (55)
Imp-321 Breast Cancer	George Washington University	P2	CCC (55)
Ipilimumab Breast Cancer	Emory University	P2	CCC (55)
Lerociclib Breast Cancer	EQRx, Inc.	P2	CCC (55)
Mirtazapine Breast Cancer	Assiut University	P3	CCC (55)
Nogitecan Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	CCC (55)
Reparixin Breast Cancer	Dompé Farmaceutici S.p.A	P2	CCC (55)
Selumetinib Breast Cancer	National Cancer Institute (NCI)	P2	CCC (55)
Sufentanyl Breast Cancer	Jun Zhang	P4	CCC (55)
Talazoparib Breast Cancer	Stanford University	P2	CCC (55)
Tocilizumab Breast Cancer	Kathy Miller	P2	CCC (55)
Trilaciclib Breast Cancer	Sun Yat-sen University	P3	CCC (55)
Zongertinib Breast Cancer	MedSIR	P2	CCC (55)
18f-flt Breast Cancer	University of Pennsylvania	P3	CCC (54)
Bcd-178 Breast Cancer	Biocad	P3	CCC (54)
Benzamide, N-[(3R)-3-(2-Chloro-5-Fluorophenyl)-6-(5-Cyano[1,2,4]Triazolo[1,5-A]Pyridin-6-Yl)-2,3-Dihydro-1-Oxo-1H-Isoindol-4-Yl]-3-Fluoro-5-(Trifluoromethyl)- Breast Cancer	Relay Therapeutics, Inc.	P3	CCC (54)

Showing 201 to 250 of 849 assets

PreviousPage 5 of 17Next